At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLSD Clearside Biomedical
Post-Market Trading 10-17 18:13:52 EDT
1.15
+0.03
+2.68%
盘后1.12
-0.03-2.61%
18:02 EDT
High1.17Low1.10Vol472.53K
Open1.11D1 Closing1.12Amplitude6.22%
Mkt Cap85.96MTradable Cap79.53MTotal Shares74.75M
T/O537.66KT/O Rate0.68%Tradable Shares69.16M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Clearside Biomedical management to meet with JMP Securities
TIPRANKS  ·  10-15
Clearside Biomedical management to meet with JMP Securities
Clearside Biomedical Is Maintained at Buy by Chardan Capital
Dow Jones  ·  10-15
Clearside Biomedical Is Maintained at Buy by Chardan Capital
Clearside Biomedical’s CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 Target
TIPRANKS  ·  10-10
Clearside Biomedical’s CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 Target
Clearside Biomedical Is Maintained at Buy by Needham
Dow Jones  ·  10-10
Clearside Biomedical Is Maintained at Buy by Needham
U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku
Reuters  ·  10-10
U.S. RESEARCH ROUNDUP-Abbott, Gilead, Roku
Clearside Biomedical Inc : Needham Raises Target Price to $6 From $4
THOMSON REUTERS  ·  10-10
Clearside Biomedical Inc : Needham Raises Target Price to $6 From $4
Clearside stock falls 12% amid Phase 2 data for CLS-AX
seekingalpha  ·  10-10
Clearside stock falls 12% amid Phase 2 data for CLS-AX
Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success
TIPRANKS  ·  10-10
Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success
Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position
TIPRANKS  ·  10-10
Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position
Stifel bullish on Clearside Biomedical as CLS-AX meets goals in Phase 2b ODYSSEY
TIPRANKS  ·  10-10
Stifel bullish on Clearside Biomedical as CLS-AX meets goals in Phase 2b ODYSSEY
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
Benzinga  ·  10-09
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
Clearside Biomedical Shares Rise 10.5% as Co's Eye Disease Drug Succeeds in Mid-Stage Trial
THOMSON REUTERS  ·  10-09
Clearside Biomedical Shares Rise 10.5% as Co's Eye Disease Drug Succeeds in Mid-Stage Trial
Clearside Biomedical’s Promising Phase 2b ODYSSEY Trial Outcomes
TIPRANKS  ·  10-09
Clearside Biomedical’s Promising Phase 2b ODYSSEY Trial Outcomes
Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data
MT Newswires Live  ·  10-09
Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data
BRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes
Reuters  ·  10-09
BRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes
BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial
Reuters  ·  10-09
BUZZ-Clearside jumps as eye disease drug succeeds in mid-stage trial
Clearside Biomedical Shares Rise 22% Premarket as Co's Eye Disease Drug Succeeds in Mid-Stage Trial
THOMSON REUTERS  ·  10-09
Clearside Biomedical Shares Rise 22% Premarket as Co's Eye Disease Drug Succeeds in Mid-Stage Trial
Clearside reports results from ODYSSEY Phase 2b trial of CLS-AXClearside Biomedical
TIPRANKS  ·  10-09
Clearside reports results from ODYSSEY Phase 2b trial of CLS-AXClearside Biomedical
Clearside Biomedical Inc - Cls-Ax Reduced Treatment Burden by 84% Over 6 Months
THOMSON REUTERS  ·  10-09
Clearside Biomedical Inc - Cls-Ax Reduced Treatment Burden by 84% Over 6 Months
Clearside Biomedical Inc - Cls-Ax Shows Well-Tolerated Safety Profile Through Week 36
THOMSON REUTERS  ·  10-09
Clearside Biomedical Inc - Cls-Ax Shows Well-Tolerated Safety Profile Through Week 36
No data available

Introduction

Company Name.
Clearside Biomedical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Issue price:
--